10-Q: TuHURA Biosciences Reports Q1 2025 Results Following Merger with Kintara Therapeutics

TuHURA Biosciences, formerly Kintara Therapeutics, released its first quarterly report post-merger, detailing financial results and operational updates including the re-initiation of the REM-001 clinical trial.

Summary

• TuHURA Biosciences, previously known as Kintara Therapeutics, has released its financial results for the quarter ended September 30, 2024.
• The company completed a merger with TuHURA Biosciences on October 18, 2024, which included a 1-for-35 reverse stock split and a name change.
• The company reported a net loss of $2.161 million for the quarter, compared to a net loss of $2.962 million for the same period last year.
• Research and development expenses decreased significantly to $252,000 from $1.859 million year-over-year, primarily due to the termination of the VAL-083 program.
• General and administrative expenses increased to $1.957 million from $1.103 million year-over-year, largely due to merger-related costs.
• The company's cash and cash equivalents stood at $3.020 million as of September 30, 2024, down from $4.909 million at the end of the previous quarter.
• The company re-initiated its REM-001 clinical trial for cutaneous metastatic breast cancer (CMBC) following a $2 million grant from the National Institutes of Health (NIH).
• The company expects to complete enrollment in the REM-001 study in the fourth calendar quarter of 2024.
• The company has issued approximately 40.4 million shares of common stock to TuHURA stockholders as part of the merger.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with some positive developments, such as the merger and re-initiation of the REM-001 trial, but is overshadowed by significant financial concerns, including a net loss, decreased cash position, and going concern uncertainty. The overall sentiment is negative due to the financial risks.

Positives

• The company successfully completed its merger with TuHURA Biosciences, which is expected to provide a more diversified oncology pipeline.
• Research and development expenses decreased significantly due to the termination of the VAL-083 program, which may lead to cost savings.
• The company re-initiated the REM-001 clinical trial, supported by a $2 million NIH grant, indicating progress in its lead program.
• The company expects to complete enrollment in the REM-001 study in the fourth calendar quarter of 2024, suggesting a clear timeline for this program.
• The company has received a Fast Track Designation from the FDA for REM-001 in CMBC.

Negatives

• The company reported a net loss of $2.161 million for the quarter, indicating ongoing financial challenges.
• General and administrative expenses increased significantly due to merger-related costs, which may impact profitability.
• The company's cash and cash equivalents decreased to $3.020 million, raising concerns about its ability to fund operations.
• The company has an accumulated deficit of $162.052 million, highlighting its history of losses.
• The company has stated that there is substantial doubt about its ability to continue as a going concern within one year.

Risks

• The company's ability to continue as a going concern is uncertain, as it has not generated any revenue and has an accumulated deficit.
• The company requires additional funding to maintain its clinical trials, research and development projects, and general operations.
• The company's ability to raise additional capital is subject to various risks and uncertainties, including global unrest.
• The company may need to tailor its drug candidate development programs based on the amount of funding it is able to raise.
• The company's clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors.
• The company's future funding requirements will depend on many factors, including the rate of progress and cost of clinical studies, and the costs of seeking regulatory approvals.

Future Outlook

The company plans to continue to pursue opportunities to secure the necessary financing through the issue of new equity, including debt, entering into strategic partnership arrangements, and/or pursuing additional strategic transactions. The company expects to complete enrollment of patients in the REM-001 Study in the fourth calendar quarter of 2024.

Management Comments

• Management is pursuing various financing alternatives to fund the company's operations.
• Management plans to continue to pursue opportunities to secure the necessary financing through the issue of new equity, including debt, entering into strategic partnership arrangements, and/or pursuing additional strategic transactions.

Industry Context

The company operates in the biopharmaceutical industry, focusing on the development of novel cancer therapies. The merger with TuHURA Biosciences is intended to create a company with a more diversified oncology pipeline. The re-initiation of the REM-001 clinical trial is a key development in the company's efforts to address unmet medical needs in cancer treatment.

Comparison to Industry Standards

• The company's research and development expenses are significantly lower than many comparable clinical-stage biopharmaceutical companies, primarily due to the termination of the VAL-083 program. For example, companies like Xencor and Iovance Biotherapeutics, which are also developing cancer therapies, typically spend significantly more on R&D.
• The increase in general and administrative expenses due to merger-related costs is not uncommon during such transactions. However, the company's G&A expenses are higher than some peers of similar size, such as Agenus, which has a more established infrastructure.
• The company's cash position of $3.020 million is relatively low compared to other clinical-stage companies, which often have tens or hundreds of millions in cash reserves. For example, companies like Celldex Therapeutics and Gritstone Bio have significantly larger cash balances.
• The company's reliance on grants and equity financing is typical for early-stage biotechs, but the uncertainty around its ability to raise additional capital is a concern. Many companies in the sector, such as BioNTech and Moderna, have secured substantial funding through partnerships and commercialization of products.
• The company's focus on photodynamic therapy (PDT) with REM-001 is a niche area within oncology, and there are few direct comparables. However, the company's clinical trial progress and regulatory milestones will be closely watched by investors in the sector.

Management Changes

Related Party Transactions

• The company has related party transactions with Valent Technologies, LLC, including royalty agreements and dividends on Series A Preferred Stock.

Stakeholder Impact

• Shareholders of Kintara Therapeutics received contingent value rights (CVRs) entitling them to receive approximately 1.5 million shares upon achieving certain milestones in the REM-001 trial.
• TuHURA stockholders now own the majority of the shares of the combined company.
• The company's employees may be impacted by the ongoing financial challenges and potential restructuring.
• The company's customers (patients) may benefit from the continued development of REM-001.
• The company's suppliers and creditors may be impacted by the company's financial instability.

Next Steps

• The company expects to complete enrollment of patients in the REM-001 Study in the fourth calendar quarter of 2024.
• The company will continue to pursue opportunities to secure the necessary financing through the issue of new equity, including debt, entering into strategic partnership arrangements, and/or pursuing additional strategic transactions.

Key Dates

Keywords

TuHURA Biosciences, Kintara Therapeutics, Merger, REM-001, Cutaneous Metastatic Breast Cancer, CMBC, Clinical Trial, Reverse Stock Split, Photodynamic Therapy, Oncology, Biopharmaceutical, NIH Grant